The present study aimed at evaluating clinical and laboratory aspects during experimental envenomation by Crotalus durissus terrificus in dogs treated with antiophidic serum. Twenty-one dogs were divided into three groups of seven animals each. Group I received 1mg/kg venom (sc); Group II received 1mg/kg venom (sc), 50mg antiophidic serum (iv), and fluid therapy including 0.9% NaCl solution (iv); and Group III received 1mg/kg venom (sc), 50mg antiophidic serum (iv), and fluid therapy including 0.9% NaCl solution containing sodium bicarbonate diluted to the dose of 4mEq/kg. The clinical signs of ataxia, sedation, flaccid paralysis, mydriasis, eyeball paralysis, mandible ptosis, sialorrhea, vomiting and diarrhea observed in the dogs were very similar to those observed in humans. The decrease in hemoglobin, hematocrit, erythrocyte, platelet and fibrinogen levels, prolongation of clotting time, prothrombin time (PT) and activated partial thromboplastin time (APTT), as well as hypocellularity in the bone marrow characterized anemia, thrombocytopenia and blood incoagulability, as well as hypofibrinogenemia and decreased bone-marrow activity. Important bleeding was not observed. Increased numbers of leukocytes and neutrophils and decreased numbers of lymphocytes and eosinophils characterized an acute inflammatory response and stress caused by generalized pain. The employed antiophidic serum was effective and all animals survived.
INTRODUCTION
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The genus Crotalus of the family Crotalidae and its subspecies Crotalus durissus terrificus are the second most important cause of accidents in Brazil. Crotalus snakes are considered more venomous than snakes of the Bothrops genus (10) . The genus Crotalus is of great importance as the venom of its members causes severe clinical aspects and most of the times can be fatal when treatment with specific anti-serum is not quickly instituted (10, 12) . Crotalus venom is constituted of several fractions including the following toxins: crotoxin, crotamine, giroxin, and convulxin (9, 30, 31) .
It has three main actions: neurotoxic (11) , myotoxic (3, 4) and hemolytic (33) . The major complications observed in Crotalus envenomation are acute renal failure and tubular necrosis (23, 28, 33) .
MATERIALS AND METHODS
The present experiment was approved by the Ethics Committee of University of Western São Paulo, UNOESTE, Presidente Prudente, Brazil.
Twenty-one dogs (1-4 years old; no defined breed; 4-15kg) from the Central Kennel of UNOESTE were used. Based on a complete physical examination and laboratory tests, animals that presented normal values were selected (22) . They were kept in individual stalls at the kennel of the Veterinary Hospital of UNOESTE and received water and food ad libitum.
Animals were divided into three groups of seven animals each, Group I: animals inoculated with crotalic venom (1mg/kg); Group II: animals inoculated with crotalic venom (1mg/kg) and treated with antiophidic serum (50mg) and fluid therapy including 0.9% NaCl solution 6h after venom inoculation (AV); Group III: animals inoculated with crotalic venom (1mg/kg), and treated with antiophidic serum (50mg) and fluid therapy including 0.9% NaCl solution containing sodium bicarbonate diluted to the dose of 4mEq/Kg 6h after venom inoculation (AV).
Antiophidic serum (bothropic-crotalic) was from Vencofarma Laboratory (serum sample 001/03); each flask of 10ml serum neutralizes 10mg crotalic venom. Clinical evaluation included heart and breathing frequencies, pulse rate, temperature, locomotion, sedation and muscle rigidity degrees, pupil diameter, sialorrhea, vomit and diarrhea. Laboratory tests included blood cell count (blood samples were collected by jugular vein puncture using Vacutainer test tubes for hemogram), clotting time (19) , coagulogram (blood samples were collected by jugular vein puncture using Vacutainer tubes containing citrate) and myelogram (samples were collected by iliac crest puncture using a special needle for bone marrow biopsy and aspiration) (1, 7) at different moments according to table 1. 
Statistical analysis
Each variable was studied by analysis of repeated measures or profiles (25) of differences between each evaluation moment and the control moment in Groups I, II and III throughout the experiment.
For variables whose results were given by scores, groups were compared at every moment using Kruskal-Wallis non-parametric test, and the effect of moments on each group was compared using Friedman non-parametric test (25, 35 
RESULTS AND DISCUSSION
Clinical evaluation
Discreet edema and discomfort was observed at the venom inoculation sites in all groups.
Animals of all three groups presented ataxia and sedation at M1, which persisted until 72h AV in Groups II and III and until 144h AV in Group I.
Flaccid paralysis of facial muscles, generalized myalgia, eyeball paralysis, mandible ptosis, and phonation and deglutition difficulties were observed at M1 (p <0.05) in Groups I and III, which returned to normality at M2. The venom has effects on the central nervous system, compromising the III (oculomotor), IV (trochlear), VI (abducent) and XI (accessory) cranial nerves and peripheral nervous system (8, 16, 29, 30) . The observed clinical alterations are attributed to the venom neurotoxic (2, 20) and myotoxic activities (3, 6) .
Temperature, breathing and heart frequencies and pulse rate did not show any significant difference among moments for each group nor among groups for each moment.
Moderate sialorrhea was observed in 28. Leukocytosis with neutrophilia can be caused by the interaction between the crotalic venom and the animal organism, inducing a typical acute-phase response with release of catecholamines, cellular mediators and humor, besides serum chemotactic factors. Leukocytosis with neutrophilia has also been reported in the initial phase of crotalic envenomation in humans (20, 26, 32, 34) and animals (14, 27, 29, 36, 38) .
The decrease in the number of lymphocytes and eosinophils, although not significant and within normal values for the species, characterized stress probably caused by the pain in all three groups at M1 (20, 27, 36) .
Decreased platelet numbers were noticed in all three groups at M2 and M3, relative to the control moment.
Clotting time
Evaluation of the clotting time showed a significant alteration in all thee groups at M1.
Eighteen hours after the antiophidic serum administration, clotting time returned to normality in animals of Groups II and III but kept high in animals of Group I (13, 29, 37) .
Alteration in the clotting time is due to the venom fraction named "thrombin-like", capable of converting fibrinogen into fibrin, leading the patient to hypofibrinogenemia, which culminates with prolongation of clotting time (13, 37, 29) .
Recently, clinical and laboratory investigations were carried out in 24 patients bitten by Crotalus durissus revealing hypofibrinogenemia as well as secondary fibrinolytic activation. Some of these patients also presented consumption of coagulation factors V and VIII, as well as generation of intravascular thrombin, which could not be explained by the thrombin-like activity of this venom (32) .
Coagulogram
Prothrombin time (PT) and activated partial thromboplastin time (APTT) significantly prolonged at M1 and M2 in animals of all three groups. At M3 and M4, animals of Group I continued presenting significant PT and APTT prolongation.
Prolonged PT and APTT and decreased fibrinogen levels suggest a possible compromising of other factors of the extrinsic or intrinsic pathway and factors that are common to both pathways of the coagulation cascade (5, 15, 16, 17, 36 
Myelogram
Normal cells were observed at control moment ( Figure 1A ) and at M2 (Figure 1 C) with conserved maturation and normal mitoses for all cell series, including erythroid and myeloid series. At M1, bone marrow was hypocellular in all three groups ( Figure   1B ), together with relative hypoplasia of the erythroid series in all three groups, absolute hyperplasia of the myeloid series in Group I and relative hyperplasia in Groups II and III.
A decrease in erythropoiesis and granulopoiesis, intensified by the increased myeloid:erythroid (M:E) ratio, was observed. An integrated analysis with peripheral blood showed inflammation, characterized in blood cell count as an increase in the numbers of leukocytes and segmented neutrophils (19) .
There were not alterations in the megakaryocytic series for all three groups, characterizing normality.
Although megakaryocyte count was not carried out, megakaryocytic hypoplasia was suggested at M1. 
CONCLUSION
The observed clinical alterations, such as generalized pain, discreet edema, generalized flaccid paralysis, eyeball paralysis, mydriasis, mandible ptosis, sialorrhea, vomiting and diarrhea, are very similar to those caused by crotalic envenomation in humans.
There was a decrease in erythrocyte, hemoglobin and hematocrit levels, characterizing anemia as a consequence of the venom hemolytic action. Leukocytosis with neutrophilia occurred as a typical inflammatory acute-phase response and due to the inflammation at the venom inoculation site.
The decrease in the number of lymphocytes and eosinophils characterized stress mainly caused by the generalized pain.
Crotalic venom caused a decrease in platelet number, hypocellularity in the bone marrow, and a decrease in fibrinogen levels six hours after the venom inoculation.
The decrease in fibrinogen levels justifies the prolonged prothrombin time and activated partial thromboplastin time.
Blood incoagulability was the most frequently observed laboratory alteration starting one hour after venom inoculation and returning to normality 18 hours after therapy using antiophidic serum.
Although blood incoagulability and thrombocytopenia were observed, there was not important bleeding.
The antiophidic serum therapy administered six hours after venom inoculation, was effective in preventing death and in restoring the animals' clinical conditions.
